About us
Years of research. 

Millions in funding. 

One breakthrough product.

Rejuvant® is the breakthrough product of Ponce de Leon Health, founded by Tom Weldon, inventor, entrepreneur, and investor who has launched 12 companies in the medical device and healthcare sector and holds 30 patents for medical devices. 

In 2014, Tom turned his attention to the anti-aging sector, and entered into a research agreement with the Buck Institute for Research on Aging, the foremost aging research institute in the world. The goal of the research: develop a safe, affordable, science-backed, non-drug product that offers people the opportunity to live healthier and longer lives. The result of this sponsored research with the Buck Institute is Rejuvant, the first life-enhancing product from Ponce de Leon Health.

Our Vision: 

Live better, longer, and enjoy life more.

At Ponce De Leon Health, our vision is simple: enable people to add more healthy years to their lifespan. We saw that thanks to medical interventions, people were living longer. But that didn’t necessarily mean they were living better. We thought, “What if we could increase the years people stay healthy and active?” Our quest to find answers to this question drives us every single day.
Our Mission: Turn anti-aging research into solutions that defy the aging process.
We transform breakthroughs coming out of research labs that study the science of aging into safe, effective products that extend healthspan, so people can lead healthier, more active, productive lives.
Tom Weldon 
Tom has 35 years of senior management experience, primarily in the medical device industry, in both early stage and public companies. He is a well-known entrepreneur and venture capitalist, and holds more than two-dozen patents. He has founded over a dozen companies, which have created over $2 billion in shareholder value. The venture fund Tom co-founded, Accuitive Medical Ventures, has raised a total of $230 million across two funds, and is now fully invested.
Dr. Brian K. Kennedy
Brian K. Kennedy earned a Ph.D. from the Massachusetts Institute of Technology, and has established an international reputation for his work in the fundamental biology of aging. He became the Buck Institute’s second CEO in July 2010, coming from the University of Washington in Seattle where he served in the Department of Biochemistry. He is currently Professor and Director of the Center for Healthy Aging at the National University of Singapore. Dr. Kennedy has served on the National Institutes of Health Cellular Mechanisms of Aging and Development, and has published more than 60 manuscripts in prestigious journals including Cell, Nature, Science, and the Proceedings of the National Academy of Sciences. He has been an Associate Editor for the Journal of Gerontology since 2006.